Daraxonrasib in Metastatic Pancreatic Cancer (RASolute 302) @NEJMgroup
Daraxonrasib in Metastatic Pancreatic Cancer (RASolute 302) @NEJMgroup
Uploaded July 2026 | Updated September 2026, 1 week ago
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy.

Read the full phase 3 RASolute 302 trial results and Research Summary at NEJM.org.

#oncology #gastroenterology #nejm
Daraxonrasib in Metastatic Pancreatic Cancer (RASolute 302)Ask the Expert — Risk Prevention Tools for Cardiovascular DiseaseThe Whole Patient — Toward Holistic, High-Value Care | NEJMNEJM Interview: Justin Barr on physician leadership in American society and politics over the pas...Image Challenge — April 9, 2026Modern Presidential Leadership and Health Care’s Defining MomentsClinical Decisions: Liver Transplantation in Alcohol-Related Liver DiseaseClinical Practice: Secondary Prevention after Ischemic StrokeNEJM Interview: Marcus Hughes on inconsistent oversight of psychedelic agents at the state and fe...The Myth of Race and GeneticsHow Did Race Get Into Lung Testing?Image Challenge — July 30, 2026
NEJM Group |

Daraxonrasib in Metastatic Pancreatic Cancer (RASolute 302)

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER